A decade of experience in over 300 surgically treated spine patients with long-term oral anticoagulation: a propensity score matched cohort study

Eur Spine J. 2024 Apr;33(4):1360-1368. doi: 10.1007/s00586-024-08134-8. Epub 2024 Feb 21.

Abstract

Purpose: The aim of this study was to investigate the risks and outcomes of patients with long-term oral anticoagulation (OAC) undergoing spine surgery.

Methods: All patients on long-term OAC who underwent spine surgery between 01/2005 and 06/2015 were included. Data were prospectively collected within our in-house Spine Surgery registry and retrospectively supplemented with patient chart and administrative database information. A 1:1 propensity score-matched group of patients without OAC from the same time interval served as control. Primary outcomes were post-operative bleeding, wound complications and thromboembolic events up to 90 days post-surgery. Secondary outcomes included intraoperative blood loss, length of hospital stay, death and 3-month post-operative patient-rated outcomes.

Results: In comparison with the control group, patients with OAC (n = 332) had a 3.4-fold (95%CI 1.3-9.0) higher risk for post-operative bleeding, whereas the risks for wound complications and thromboembolic events were comparable between groups. The higher bleeding risk was driven by a higher rate of extraspinal haematomas (3.3% vs. 0.6%; p = 0.001), while there was no difference in epidural haematomas and haematoma evacuations. Risk factors for adverse events among patients with OAC were mechanical heart valves, posterior neck surgery, blood loss > 1000 mL, age, female sex, BMI > 30 kg/m2 and post-operative PTT levels. At 3-month follow-up, most patients reported favourable outcomes with no difference between groups.

Conclusion: Although OAC patients have a higher risk for complications after spine surgery, the risk for major events is low and patients benefit similarly from surgery.

Keywords: Bleeding; Epidural haematoma; Mechanical heart valve; Oral anticoagulation; Spine surgery; Vitamin K antagonist.

MeSH terms

  • Administration, Oral
  • Anticoagulants* / adverse effects
  • Cohort Studies
  • Female
  • Hematoma / chemically induced
  • Humans
  • Postoperative Hemorrhage / drug therapy
  • Propensity Score
  • Retrospective Studies
  • Risk Factors
  • Thromboembolism*

Substances

  • Anticoagulants